Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

It is of interest to pinpoint SARS-CoV-2 sequence features defining vaccine resistance. In the ENSEMBLE randomized, placebo-controlled phase 3 trial, estimated single-dose Ad26.COV2.S vaccine efficacy (VE) was 56% against moderate to severe–critical COVID-19. SARS-CoV-2 Spike sequences were measured...

Descripción completa

Detalles Bibliográficos
Autores principales: Magaret, Craig, Li, Li, deCamp, Allan, Rolland, Morgane, Juraska, Michal, Williamson, Brian, Ludwig, James, Molitor, Cindy, Benkeser, David, Luedtke, Alex, Simpkins, Brian, Carpp, Lindsay, Bai, Hongjun, Deariove, Bethany, Greninger, Alexander, Roychoudhury, Pavitra, Sadoff, Jerald, Gray, Glenda, Roels, Sanne, Vandebosch, An, Stieh, Daniel, Le Gars, Mathieu, Vingerhoets, Johan, Grinsztejn, Beatriz, Goepfert, Paul, Truyers, Carla, Van Dromme, Ilse, Swann, Edith, Marovich, Mary, Follmann, Dean, Neuzil, Kathleen, Corey, Lawrence, Hyrien, Ollivier, Paiva de Sousa, Leonardo, Casapia, Martin, Losso, Marcelo, Little, Susan, Gaur, Aditya, Bekker, Linda-Gail, Garrett, Nigel, Heng, Fei, Sun, Yanqing, Gilbert, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312950/
https://www.ncbi.nlm.nih.gov/pubmed/37398105
http://dx.doi.org/10.21203/rs.3.rs-2743022/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312950/
https://www.ncbi.nlm.nih.gov/pubmed/37398105
http://dx.doi.org/10.21203/rs.3.rs-2743022/v1

Ejemplares similares